Učitavanje...
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
Better understanding of roles of complement in pathology has fuelled an explosion of interest in complement-targeted therapeutics. The C5-blocking monoclonal antibody (mAb) eculizumab, the first of the new wave of complement blocking drugs, was FDA approved for treatment of Paroxysmal Nocturnal Hemo...
Spremljeno u:
| Izdano u: | Front Immunol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7793867/ https://ncbi.nlm.nih.gov/pubmed/33424866 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.612402 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|